Evidence map›Paper›PMID 31119685›Full record

ReviewGenes & genomics2019

Recent trends in CRISPR-Cas system: genome, epigenome, and transcriptome editing and CRISPR delivery systems.

Taegeun Bae, Junseok W Hur, Dokyoung Kim, Junho K Hur

Abstract readReview
PubMed Publisher
In one paragraph

Review in Genes & genomics, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed.

  1. Article
  2. Review
  3. Review
  4. Review
  5. Review
  6. Review
  7. In Search of Molecular Markers for Cerebellar Neurons.International journal of molecular sciences · 2021
    Review
  8. KRAB-Induced Heterochromatin Effectively SilencesInternational journal of molecular sciences · 2020
    Article
  9. Article
  10. Article
  11. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Taegeun BaeDepartment of Medicine, Graduate School, Kyung Hee University, Seoul, South Korea.
Junseok W HurDepartment of Neurosurgery, College of Medicine, Korea University, Seoul, South Korea.
Dokyoung KimDepartment of Anatomy and Neurobiology, College of Medicine, Kyung Hee University, Seoul, 02447, Republic of Korea. dkim@khu.ac.kr.
Junho K HurDepartment of Biomedical Science, Graduate School, Kyung Hee University, Seoul, South Korea. jhur@khu.ac.kr.ORCID 0000-0003-3794-1149

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThe CRISPR-Cas systems have emerged as a robust genome editing tool useful in various fields of research. With the discovery and development of the orthologous CRISPR-Cas systems, their genome editing efficiency have improved.

objectiveIn this review, we aim to present the recent developments and applications of the CRISPR-Cas systems.

methodsFirst, we introduce how the advancements of CRISPR technology enabled genome editing to single base precision. Then, we discuss the CRISPR based methods for targeted transcriptional regulation, epigenome editing, and RNA editing. Finally, we review the CRISPR delivery systems highlighting recent attempts to integrate nanotechnology to develop novel CRISPR delivery modalities.

conclusionHere, we review the recent trends in CRISPR-based biotechnologies, encompassing genome editing, epigenome regulation and direct RNA targeting and provide an overview of methods employed for CRISPR delivery with an emphasis on the most recent nanotechnology-based delivery strategies. We anticipate that the development of CRISPR based technology will continue to explore novel methods.

Indexed as

CRISPR-Cas SystemsAnimalsEpigenomicsGene EditingGene Transfer TechniquesHumansTranscriptomeCRISPR-Cas systemDeliveryEpigeneticsGenome editingRNA editing

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.